Oncopeptides has announced the signing of an exclusive distribution and commercialisation agreement with Salus Group, one of the leading pharmaceutical distributors in Central and Eastern Europe (the CEE region), for its flagship drug Pepaxti.
Under the terms of the agreement, Salus is granted exclusive rights to market and sell Pepaxti in 11 different CEE markets, including Croatia, Hungary, Poland and Bulgaria.
According to company estimates, the CEE region represents approximately 150 million SEK in market potential. The new agreement will also enable earlier-than-planned sales uptake in the CEE region.
"We are proud to partner with Oncopeptides to bring this important therapy to patients across the CEE region," said Žiga Hieng, CEO of Salus.
At Salus, our mission is to bridge the gap between medical innovation and the patients who need it most."
We look forward to leveraging our deep local expertise to ensure that patients in these key markets gain access to Pepaxti as quickly as possible.
Salus will handle local regulatory processes, market access and commercialisation in the designated territories, while Oncopeptides will maintain overall responsibility for the drug's manufacturing and supply.
Sales revenue generated in the agreed territories will be shared between Oncopeptides and Salus, with Oncopeptides entitled to a larger portion of the revenue.
"We are very pleased to enter this partnership with Salus, whose strong regional presence and expertise make them the ideal partner for this market," added Sofia Heigis, CEO of Oncopeptides.
"This agreement enables us to make Pepaxti available to patients in Central and Eastern Europe faster than originally planned."
We see significant strategic value in the fact that revenue streams from these markets are now projected to arrive earlier than assumed in our previous launch strategy.